Changeflow GovPing Healthcare FDA CDER Final Response Letter to AdventaPharma...
Routine Enforcement Added Final

FDA CDER Final Response Letter to AdventaPharma DWC-LLC

Favicon for www.regulations.gov Regs.gov: Food and Drug Administration
Detected March 24th, 2026
Email

Summary

The FDA's Center for Drug Evaluation and Research (CDER) has issued a final response letter to AdventaPharma DWC-LLC. This document is part of the ongoing regulatory process for drug applications and does not appear to contain new compliance obligations.

View original document View source feed page

What changed

The FDA's Center for Drug Evaluation and Research (CDER) has issued a final response letter to AdventaPharma DWC-LLC, identified by docket number FDA-2025-P-5582-0003. This communication is part of the standard regulatory review process for pharmaceutical products and does not introduce new compliance requirements or penalties for other entities.

As this is a specific response to a company's submission, there are no immediate required actions for other regulated entities. Compliance officers should note this as part of the FDA's ongoing regulatory activities in the pharmaceutical sector. No compliance deadline or penalty information is applicable to this specific document.

Source document (simplified)

Content

There are no documents available to view or download

Attachments 1

Final Response Letter from FDA CDER to AdventaPharma DWC-LLC

More Information
- Author(s) CDER
Download

Related changes

Favicon for www.regulations.gov FDA Complaint Document
Routine Mar 24, 2026 • Regs.gov: Food and Drug Administration • Healthcare
Favicon for www.regulations.gov FDA Complaint Received
Routine Mar 24, 2026 • Regs.gov: Food and Drug Administration • Healthcare
Favicon for www.regulations.gov FDA Completeness Assessment Correspondence
Routine Mar 24, 2026 • Regs.gov: Food and Drug Administration • Healthcare
Favicon for www.oplc.nh.gov Walmart Pharmacy Disciplinary Final Order
Priority review Mar 24, 2026 • NH Board of Pharmacy Actions • Pharma & Drug Safety
Favicon for changeflow.com Lithium-ion Electrochemical Element Patent with High Power
Routine Mar 24, 2026 • ChangeBridge: EPO Bulletin - Batteries (H01M) • Energy
Favicon for changeflow.com Battery Pack and Vehicle Design with Heat Sink Patent Application
Routine Mar 24, 2026 • ChangeBridge: EPO Bulletin - Batteries (H01M) • Energy

Source

Favicon for www.regulations.gov
Regs.gov: Food and Drug Administration regulations.gov/search?agencyIds=FDA&sortBy=postedDate&sortDirection=desc
Healthcare
Analysis generated by AI. Source diff and links are from the original.

Classification

Agency
FDA
Instrument
Enforcement
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
FDA-2025-P-5582-0003
Docket
FDA-2025-P-5582-0003

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Drug Approval
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Compliance
Compliance frameworks
FDA 21 CFR Part 11 GxP
Topics
Drug Approval Regulatory Compliance

Browse Categories

Agriculture & Food Safety 61 Banking & Finance 234 Consumer Protection 40 Courts & Legal 324 Data Privacy & Cybersecurity 64 Defense & National Security 48 Education 20 Energy 104 Environment 83 Government & Legislation 259 Healthcare 131 Housing 16 Immigration 9 Insurance 56 Labor & Employment 111 Legal & Courts 1 Pharma & Drug Safety 99 Securities & Markets 79 Tax 63 Telecom & Technology 47 Trade & Sanctions 124 Transportation 56

Get Healthcare alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get alerts for this source

We'll email you when Regs.gov: Food and Drug Administration publishes new changes.

Free. Unsubscribe anytime.